FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1784908577> ?p ?o ?g. }

• W1784908577 endingPage "598" @default.
• W1784908577 startingPage "592" @default.
• W1784908577 abstract "BackgroundExtreme-risk patients (ie, Society of Thoracic Surgeons [STS] risk 15% or higher) with severe aortic valve stenosis may not obtain mortality benefit from aortic valve replacement (AVR). We reviewed our experience with this group of patients to better understand our triage process and outcomes.MethodsWe performed a retrospective review of 97 patients with severe aortic valve stenosis and STS risk of 15% or higher treated from 2008 through 2013. The median patient age was 85 years (minimum, 44; maximum, 97 years), and 47 patients (48.5%) were male. The STS risk of mortality was 19.8% (minimum, 15.1%; maximum, 60.9%). Patients were assigned to treatment groups based on the first aortic valve intervention of balloon aortic valvuloplasty (BAV group, 66 [68%]) or de novo AVR (d-AVR group, 31 [32%]).ResultsPatients in the BAV group were sicker, with a reduced ejection fraction (0.35 vs 0.57; p = 0.002) and greater prevalence of urgent/emergency operative status (32% vs 10%; p = 0.004) compared with those in the d-AVR group. After BAV, 33 patients (50%) demonstrated clinical improvement and went on to receive subsequent staged AVR after a median of 64 days (minimum, 3; maximum, 390 days). The mortality rate at 2 years was worse in the BAV group (57.3% ± 6.3%) than in the d-AVR group (29.5% ± 8.3%; p = 0.015), but was similar in patients who received BAV followed by staged AVR and de novo AVR (p = 0.426).ConclusionsBAV may triage select patients with STS risk 15% or higher who are questionable candidates for AVR. Patients with clinical improvement after BAV experience benefit from staged AVR. Extreme-risk patients (ie, Society of Thoracic Surgeons [STS] risk 15% or higher) with severe aortic valve stenosis may not obtain mortality benefit from aortic valve replacement (AVR). We reviewed our experience with this group of patients to better understand our triage process and outcomes. We performed a retrospective review of 97 patients with severe aortic valve stenosis and STS risk of 15% or higher treated from 2008 through 2013. The median patient age was 85 years (minimum, 44; maximum, 97 years), and 47 patients (48.5%) were male. The STS risk of mortality was 19.8% (minimum, 15.1%; maximum, 60.9%). Patients were assigned to treatment groups based on the first aortic valve intervention of balloon aortic valvuloplasty (BAV group, 66 [68%]) or de novo AVR (d-AVR group, 31 [32%]). Patients in the BAV group were sicker, with a reduced ejection fraction (0.35 vs 0.57; p = 0.002) and greater prevalence of urgent/emergency operative status (32% vs 10%; p = 0.004) compared with those in the d-AVR group. After BAV, 33 patients (50%) demonstrated clinical improvement and went on to receive subsequent staged AVR after a median of 64 days (minimum, 3; maximum, 390 days). The mortality rate at 2 years was worse in the BAV group (57.3% ± 6.3%) than in the d-AVR group (29.5% ± 8.3%; p = 0.015), but was similar in patients who received BAV followed by staged AVR and de novo AVR (p = 0.426). BAV may triage select patients with STS risk 15% or higher who are questionable candidates for AVR. Patients with clinical improvement after BAV experience benefit from staged AVR." @default.
• W1784908577 created "2016-06-24" @default.
• W1784908577 creator A5001854695 @default.
• W1784908577 creator A5012351048 @default.
• W1784908577 creator A5026755433 @default.
• W1784908577 creator A5041560526 @default.
• W1784908577 creator A5043861019 @default.
• W1784908577 creator A5058122974 @default.
• W1784908577 creator A5073025689 @default.
• W1784908577 creator A5086188803 @default.
• W1784908577 creator A5086970664 @default.
• W1784908577 date "2016-02-01" @default.
• W1784908577 modified "2023-10-18" @default.
• W1784908577 title "The Role of Balloon Aortic Valvuloplasty in Patients With Aortic Valve Stenosis and Society of Thoracic Surgeons Risk of 15% or Higher" @default.
• W1784908577 cites W1988482331 @default.
• W1784908577 cites W2006056335 @default.
• W1784908577 cites W2037507673 @default.
• W1784908577 cites W2074661666 @default.
• W1784908577 cites W2117659108 @default.
• W1784908577 cites W2121947900 @default.
• W1784908577 cites W2132585880 @default.
• W1784908577 cites W2149609916 @default.
• W1784908577 cites W2165258820 @default.
• W1784908577 doi "https://doi.org/10.1016/j.athoracsur.2015.07.030" @default.
• W1784908577 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26410157" @default.
• W1784908577 hasPublicationYear "2016" @default.
• W1784908577 type Work @default.
• W1784908577 sameAs 1784908577 @default.
• W1784908577 citedByCount "18" @default.
• W1784908577 countsByYear W17849085772016 @default.
• W1784908577 countsByYear W17849085772017 @default.
• W1784908577 countsByYear W17849085772018 @default.
• W1784908577 countsByYear W17849085772019 @default.
• W1784908577 countsByYear W17849085772020 @default.
• W1784908577 countsByYear W17849085772021 @default.
• W1784908577 countsByYear W17849085772022 @default.
• W1784908577 crossrefType "journal-article" @default.
• W1784908577 hasAuthorship W1784908577A5001854695 @default.
• W1784908577 hasAuthorship W1784908577A5012351048 @default.
• W1784908577 hasAuthorship W1784908577A5026755433 @default.
• W1784908577 hasAuthorship W1784908577A5041560526 @default.
• W1784908577 hasAuthorship W1784908577A5043861019 @default.
• W1784908577 hasAuthorship W1784908577A5058122974 @default.
• W1784908577 hasAuthorship W1784908577A5073025689 @default.
• W1784908577 hasAuthorship W1784908577A5086188803 @default.
• W1784908577 hasAuthorship W1784908577A5086970664 @default.
• W1784908577 hasBestOaLocation W17849085771 @default.
• W1784908577 hasConcept C126322002 @default.
• W1784908577 hasConcept C139059822 @default.
• W1784908577 hasConcept C141071460 @default.
• W1784908577 hasConcept C164705383 @default.
• W1784908577 hasConcept C2776570981 @default.
• W1784908577 hasConcept C2778198053 @default.
• W1784908577 hasConcept C2780007028 @default.
• W1784908577 hasConcept C2780714102 @default.
• W1784908577 hasConcept C2781414266 @default.
• W1784908577 hasConcept C2781436128 @default.
• W1784908577 hasConcept C71924100 @default.
• W1784908577 hasConcept C78085059 @default.
• W1784908577 hasConceptScore W1784908577C126322002 @default.
• W1784908577 hasConceptScore W1784908577C139059822 @default.
• W1784908577 hasConceptScore W1784908577C141071460 @default.
• W1784908577 hasConceptScore W1784908577C164705383 @default.
• W1784908577 hasConceptScore W1784908577C2776570981 @default.
• W1784908577 hasConceptScore W1784908577C2778198053 @default.
• W1784908577 hasConceptScore W1784908577C2780007028 @default.
• W1784908577 hasConceptScore W1784908577C2780714102 @default.
• W1784908577 hasConceptScore W1784908577C2781414266 @default.
• W1784908577 hasConceptScore W1784908577C2781436128 @default.
• W1784908577 hasConceptScore W1784908577C71924100 @default.
• W1784908577 hasConceptScore W1784908577C78085059 @default.
• W1784908577 hasIssue "2" @default.
• W1784908577 hasLocation W17849085771 @default.
• W1784908577 hasLocation W17849085772 @default.
• W1784908577 hasOpenAccess W1784908577 @default.
• W1784908577 hasPrimaryLocation W17849085771 @default.
• W1784908577 hasRelatedWork W1425714727 @default.
• W1784908577 hasRelatedWork W2011310065 @default.
• W1784908577 hasRelatedWork W2028554734 @default.
• W1784908577 hasRelatedWork W2035507842 @default.
• W1784908577 hasRelatedWork W2040548955 @default.
• W1784908577 hasRelatedWork W2058118737 @default.
• W1784908577 hasRelatedWork W2290788483 @default.
• W1784908577 hasRelatedWork W2334341306 @default.
• W1784908577 hasRelatedWork W2920644863 @default.
• W1784908577 hasRelatedWork W3012063301 @default.
• W1784908577 hasVolume "101" @default.
• W1784908577 isParatext "false" @default.
• W1784908577 isRetracted "false" @default.
• W1784908577 magId "1784908577" @default.
• W1784908577 workType "article" @default.